Guy De La Rosa

2.2k total citations · 1 hit paper
36 papers, 1.7k citations indexed

About

Guy De La Rosa is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Guy De La Rosa has authored 36 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hepatology, 13 papers in Infectious Diseases and 12 papers in Epidemiology. Recurrent topics in Guy De La Rosa's work include Hepatitis C virus research (19 papers), HIV/AIDS drug development and treatment (13 papers) and Liver Disease Diagnosis and Treatment (10 papers). Guy De La Rosa is often cited by papers focused on Hepatitis C virus research (19 papers), HIV/AIDS drug development and treatment (13 papers) and Liver Disease Diagnosis and Treatment (10 papers). Guy De La Rosa collaborates with scholars based in United States, Belgium and United Kingdom. Guy De La Rosa's co-authors include Oliver Lenz, Ronald Kalmeijer, Rekha Sinha, Jane Scott, Monika Peeters, Maria Beumont‐Mauviel, Sivi Ouwerkerk‐Mahadevan, Ira M. Jacobson, Eric Lawitz and Bart Fevery and has published in prestigious journals such as The Lancet, Gastroenterology and Hepatology.

In The Last Decade

Guy De La Rosa

35 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

2014 333 citations Ira M. Jacobson, Gregory J. Dore et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guy De La Rosa United States	14	1.4k	1.2k	513	124	115	36	1.7k
Franco Felizarta United States	15	982 0.7×	847 0.7×	691 1.3×	80 0.6×	311 2.7×	37	1.4k
Timothy Eley United States	21	1.3k 1.0×	1.1k 0.9×	704 1.4×	151 1.2×	62 0.5×	52	1.8k
José Vicente Fernández-Montero Spain	21	749 0.5×	712 0.6×	441 0.9×	44 0.4×	159 1.4×	59	1.1k
Claudia Martorell United States	14	629 0.5×	598 0.5×	467 0.9×	129 1.0×	217 1.9×	28	1.3k
Daniel E. Cohen United States	19	1.4k 1.1×	1.3k 1.0×	491 1.0×	111 0.9×	37 0.3×	55	1.6k
Nathalie Adda United States	18	2.0k 1.4×	1.8k 1.4×	685 1.3×	181 1.5×	123 1.1×	55	2.3k
Benjamin Maasoumy Germany	25	1.7k 1.2×	1.5k 1.2×	305 0.6×	76 0.6×	27 0.2×	140	2.1k
Maria Beumont‐Mauviel Belgium	18	1.8k 1.3×	1.6k 1.3×	526 1.0×	183 1.5×	50 0.4×	40	2.0k
Jonathan McCone United States	12	3.5k 2.6×	3.1k 2.5×	700 1.4×	355 2.9×	71 0.6×	20	3.7k
Sarah Arterburn United States	19	2.3k 1.7×	2.3k 1.8×	398 0.8×	52 0.4×	35 0.3×	47	2.7k

Countries citing papers authored by Guy De La Rosa

Since Specialization

Citations

This map shows the geographic impact of Guy De La Rosa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy De La Rosa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy De La Rosa more than expected).

Fields of papers citing papers by Guy De La Rosa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guy De La Rosa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy De La Rosa. The network helps show where Guy De La Rosa may publish in the future.

Co-authorship network of co-authors of Guy De La Rosa

This figure shows the co-authorship network connecting the top 25 collaborators of Guy De La Rosa. A scholar is included among the top collaborators of Guy De La Rosa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guy De La Rosa. Guy De La Rosa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Carter, Darrick, et al.. (2025). The success of toll-like receptor 4 based vaccine adjuvants. Vaccine. 61. 127413–127413. 3 indexed citations

Rosa, Guy De La, Esther Papaseit, Lourdes Poyatos, et al.. (2025). Acute pharmacological effects of α-PVP in humans: a naturalistic observational study. Frontiers in Pharmacology. 16. 1626692–1626692. 1 indexed citations

Montané, Eva, Yolanda Sanz, Clara Pérez‐Mañá, et al.. (2024). Spontaneous adverse drug reactions reported in a thirteen-year pharmacovigilance program in a tertiary university hospital. Frontiers in Pharmacology. 15. 1427772–1427772.

Yuen, Man‐Fung, Wan‐Long Chuang, Cheng‐Yuan Peng, et al.. (2024). Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients. Clinical and Molecular Hepatology. 30(3). 375–387. 1 indexed citations

Feld, Jordan J., Eric Lawitz, Tuan Nguyen, et al.. (2022). EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B. Antiviral Therapy. 27(6). 3867489102–3867489102. 9 indexed citations

Feld, Jordan J., Eric Lawitz, Tuan Thanh Nguyen, et al.. (2022). EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: final results of a 28-day phase 1b study in nuc-suppressed chronic hepatitis B patients. Journal of Hepatology. 77. S848–S848. 3 indexed citations

Kwo, Paul Y., Norman Gitlin, Ronald Nahass, et al.. (2016). Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. PMC. 5 indexed citations

Overton, Edgar T., Pablo Tebas, Bruce Coate, et al.. (2016). Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial. HIV Clinical Trials. 17(2). 72–77. 13 indexed citations

Lawitz, Eric, Edwin DeJesus, Eric M. Yoshida, et al.. (2015). Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2). Hepatology. 64(2). 360–369. 142 indexed citations

10.

Lawitz, Eric, E DeJesus, Eric M. Yoshida, et al.. (2015). LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2. Journal of Hepatology. 62. S264–S265. 50 indexed citations

11.

Jacobson, Ira M., Gregory J. Dore, Graham R. Foster, et al.. (2014). Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. 384(9941). 403–413. 333 indexed citations breakdown →

12.

Manns, Michael P., Patrick Marcellin, Fred Poordad, et al.. (2014). Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 384(9941). 414–426. 278 indexed citations

13.

Dieterich, Douglas T., Jürgen K. Rockstroh, Chloe Orkin, et al.. (2014). Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study. Clinical Infectious Diseases. 59(11). 1579–1587. 45 indexed citations

14.

Forns, Xavier, Eric Lawitz, Stefan Zeuzem, et al.. (2014). Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial. Gastroenterology. 146(7). 1669–1679.e3. 187 indexed citations

15.

Aberg, Judith A., Pablo Tebas, Edgar T. Overton, et al.. (2012). Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks. AIDS Research and Human Retroviruses. 28(10). 1184–1195. 72 indexed citations

16.

Currier, Judith S., Claudia Martorell, Olayemi Osiyemi, et al.. (2011). Effects of Darunavir/Ritonavir-Based Therapy on Metabolic and Anthropometric Parameters in Women and Men Over 48 Weeks. AIDS Patient Care and STDs. 25(6). 333–340. 11 indexed citations

17.

Rosa, Guy De La, et al.. (2010). Pharmacokinetic (PK) and pharmacodynamic analyses of once‐ and twice‐daily darunavir/ritonavir (DRV/r) in the ODIN trial. Journal of the International AIDS Society. 13(S4). 11 indexed citations

18.

Rosa, Guy De La, et al.. (2009). Successful Treatment of Ectopic Cushing's Syndrome with the Long-Acting Somatostatin Analog Octreotide. Experimental and Clinical Endocrinology & Diabetes. 101(5). 319–325. 6 indexed citations

19.

Gleckman, Richard A. & Guy De La Rosa. (1998). How do the newer oral antimicrobials stack up against traditional agents?. Postgraduate Medicine. 104(4). 119–126. 1 indexed citations

20.

Rosa, Guy De La, et al.. (1987). AUTOIMMUNE POLYGLANDULAR SYNDROME, PRIMARY EMPTY SELLA, AND ACUTE LYMPHOCYTIC LEUKAEMIA. Clinical Endocrinology. 27(5). 535–543. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact